Galapagos moves AbbVie-partnered drug into PhI as multipronged attack on CF takes shape

Nick Paul Taylor Galapagos has kicked off a Phase I trial of its AbbVie-partnered cystic fibrosis (CF) drug, GLPG2222. The start of the trial marks another milestone in the rolling ...

Syros raises $40M to get its leukemia drug into Phase II

Damian Garde Syros Pharmaceuticals raised $ 40 million in equity to push forward with its pipeline of genetically targeted drugs, securing the cash it needs to take its top prospect ...

Novartis kicks it into high gear to revive flailing Alcon unit

Emily Wasserman Novartis' Alcon business has been struggling for some time now, and the company's efforts to help its eye-care business get back on track don't seem to be ...

Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

Damian Garde In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna ...

Much-hyped Moderna barrels into the clinic with 6 human trials planned for ’16

Damian Garde Moderna Therapeutics, a superlatively well-funded private biotech, has made the leap from preclinical bluster to first-in-human trials, testing out its inaugural candidate ...

Startup raises $15M to turn an old diabetes drug into a potent cancer killer

Damian Garde A group of scientists at UCLA have cooked up some compounds that could harness the cancer-fighting properties of metformin while avoiding the biological hurdles that have ...

Roche backs €19M CNS round; CRUK puts £20M into cancer vax; In womb stem cell trial to start

Nick Paul Taylor In this week's EuroBiotech Report, Ysios Capital led a €19.4 million ($ 21.7 million) investment in Minoryx Therapeutics with the support of Roche Venture ...

Intas CEO expects to break into U.S. biosimilar market yet this year

Eric Palmer The CEO of Intas Pharmaceuticals expects his company to get FDA approval this year for its biosimilar of Amgen's Neulasta, a drug it developed with Canada's Apotex. FiercePharma ...

Raptor buys into cystic fibrosis with a $418M deal

Damian Garde Rare disease biotech Raptor Pharmaceutical signed a deal to pay up to $ 418 million to Tripex Pharmaceuticals in exchange for an inhaled treatment for cystic fibrosis. FierceBiotech ...

Celgene buys into GlobeImmune’s cancer immunotherapy

Damian Garde GlobeImmune, reeling from a costly clinical failure, secured a commitment from long-time partner Celgene to collaborate on a new cancer immunotherapy. FierceBiotech News

Ackman’s ‘wolf pack’ drove Allergan into foreign hands, former CEO says

Carly Helfand Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. ...

Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes

Damian Garde A cadre of drugmakers is pressing toward late-stage trials with new injectable treatments in the long-stagnant field of migraine therapy, racing to capitalize on what analysts ...
Page 1 of 712345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS